ESMO 2024 Archives

Carcinome épidermoïde du canal anal métastatique : la première marche du podium pour POD1UM-303 Sheela RAO, SUTTON, POD1UM-303/InterAACT 2: Phase 3 Study of Retifanlimab With Carboplatin-Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal (SCAC) Not Previously Treated With Systemic Chemotherapy
SPACE-FLOT : l’intérêt (ou non) du FLOT post-op pour les adénocarcinomes gastriques non métastatiques Margaret LEE, MELBOURNE, Evaluating pathological response to guide adjuvant FLOT chemotherapy in gastroesophageal cancer (SPACE-FLOT), An international cohort study of real-world data
L’immunothérapie néoadjuvante dans les cancers coliques dMMR : des résultats historiques pour NICHE-2 ! Myriam CHALABI, AMSTERDAM, Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer : 3-year disease-free survival from NICHE-2
TNE du grêle métastatique : une histoire de coeur ! Rachel Riechelmann, Sao Paulo, Brazil, , Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumours and carcinoid syndrome: A retrospective experience of two centers of excellence
TNE avancée pré-traitée en progression? Allô CABOZANTINIB ! Jennifer Chan, Boston, United States of America, , Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses
L’immunothérapie dans le cancer colorectal métastatique pMMR : POCHI sur la bonne voie de l’infiltrat immunitaire David TOUGERON, POITIERS, Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable (pMMR/MSS) metastatic colorectal cancer and a high immune infiltrate : a proof of concept study., Preliminary results of FFCD 1703 POCHI trial
L’aspirine en adjuvant dans le cancer du colon de stade II/III : une vertu supplémentaire ? Ulrich Güller , Thun, Switzerlan, Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients: The phase III, prospective-randomized placebo-controlled multicenter SAKK 41/13 trial, , ,
Données mises à jour de l’étude IMbrave050 : adjuvant or not adjuvant ? Telle est la question ! Adam Yopp, Dallas, United States of America, , Updated efficacy and safety data from IMBRAVE050 : Phase III study of adjuvant atezolizumab + bevacizumab VS active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (HCC)
Pembrolizumab+ Lenvatinib+TACE dans le CHC de stade intermédiaire ? CA MATCHE ! Josep Llovet, Barcelona, Spain, , Transarterial chemoembolization (TACE) with or without lenvatinib (lenv) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study.,
Cancer colorectal et oxaliplatine en adjuvant : la masse musculaire pourrait-elle être la nouvelle surface corporelle pour calculer la dose de chimiothérapie ? Eric ASSENAT, Montpellier, Impact of lean body mass-based oxaliplatin dosage on neurotoxicity in adjuvant treatment of stage III colorectal caner : Final results of the phase II randomized multicenter LEANOX trial
Adénocarcinome du pancréas borderline : le mFOLFIRINOX reste invaincu LAMBERT Aurélien, Nancy - Préoperative modified FOLFIRINOX (mFOLFIRINOX) with ou without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC) : results from a randomized phase II trial PANDAS/PRODIGE 44.
La radio-chimiothérapie pré opératoire dans les cancers gastriques résécables : une promesse non tenue pour TOPGEAR Trevor LEONG, MELBOURNE, A randomised phase III trial of perioperative chemotherapy with or whithout preoperative chemoradiotherapy for resecable gastric cancer (TOPGEAR), Final results from an intergroup trial of AGITG, NHMRC CTC, TROG, EORTC and CCTG
Le pembrolizumab en néo-adjuvant dans le cancer colorectal localisé MSI/dMMR ? IMHOTEP ! Christelle De la Fouchardiere , Marseille, France, , IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors : Results of the colorectal cancer cohort.
Essai MOONLIGHT : du clair et du plus obscur ? Sylvie Lorenzen, Munich, Germany, , Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Final results of the IKF-AIO-Moonlight trial